Amylyx Pharmaceuticals (AMLX) Set to Post Quarterly Earnings on Thursday

Key Points

• Amylyx Pharmaceuticals is expected to report Q3 2026 results before market open on November 5. Analysts forecast a loss of $0.3805 per share and revenue of approximately $0.06 million.
• The company missed consensus estimates in its latest quarter, reporting a $0.39 per-share loss versus expectations of $0.36. Analysts project full-year and next-year losses of $1.48 and $1.40 per share, respectively.
• Wall Street maintains a generally positive view, with a consensus “Moderate Buy” rating and a $40.71 target price, although insiders sold 60,374 shares worth about $1.82 million in the past quarter.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3805) per share and revenue of $0.06 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post ($1.48) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Performance

AMLX opened at $28.07 on Thursday. The firm's fifty day moving average is $31.31 and its 200 day moving average is $19.88. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -19.63 and a beta of -0.10. Amylyx Pharmaceuticals has a fifty-two week low of $10.83 and a fifty-two week high of $41.14.

Wall Street Analyst Weigh In

AMLX has been the subject of several research analyst reports. Citigroup increased their target price on Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Thursday, October 15th. Robert W. Baird lifted their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a research note on Wednesday, August 19th. Wolfe Research raised Amylyx Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 17th. Mizuho upped their price target on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 18th. Finally, HC Wainwright upped their price target on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $40.71.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director M Jr sold 30,000 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.70, for a total transaction of $831,000.00. Following the completion of the transaction, the director owned 782,881 shares of the company's stock, valued at $21,685,803.70. This represents a 3.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gina Mazzariello sold 9,536 shares of the firm's stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $32.46, for a total value of $309,538.56. Following the transaction, the insider owned 190,838 shares of the company's stock, valued at approximately $6,194,601.48. The trade was a 4.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 60,374 shares of company stock worth $1,815,257 in the last quarter. 10.90% of the stock is owned by company insiders.

About Amylyx Pharmaceuticals

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.